<div class="headers"><div>Figure 3. Relative risk plot of the 30-day composite endpoint of shock/CHF. Upper panel: infarct size groups and 30-day shock/CHF by treatment strategy. Lower panel: infarct size groups and 30-day shock/CHF by treatment strategy and pre-speciﬁed 2-hour time from symptom onset to treatment randomization cut-off. *Adjusted for thrombolysis in myocardial infarction risk score. CHF indicates congestive heart failure; PI, pharmacoinvasive; PPCI, primary percutaneous coronary intervention; ULN, upper limit normal.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Figure 3. Relative risk plot of the 30-day composite endpoint of shock/CHF. </p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Upper panel: infarct size groups and 30-day shock/CHF by treatment strategy. Lower panel: infarct size groups and 30-day shock/CHF by treatment strategy and pre-speciﬁed 2-hour time from symptom onset to treatment randomization cut-off. *Adjusted for thrombolysis in myocardial infarction risk score. CHF indicates congestive heart failure; PI, pharmacoinvasive; PPCI, primary percutaneous coronary intervention; ULN, upper limit normal.</p></td>
</tr>
</tbody>
</table>
